Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Dow
Covington
Deloitte
Chinese Patent Office
Teva
Queensland Health
Argus Health
Cipla

Generated: April 21, 2018

DrugPatentWatch Database Preview

SEROQUEL XR Drug Profile

« Back to Dashboard

When do Seroquel Xr patents expire, and when can generic versions of Seroquel Xr launch?

Seroquel Xr is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-two drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.
Drug patent expirations by year for SEROQUEL XR
Pharmacology for SEROQUEL XR
Medical Subject Heading (MeSH) Categories for SEROQUEL XR
Synonyms for SEROQUEL XR
(E)-2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol
11-[4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4]thiazepine
111974-69-7
111974-72-2
2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethan-1-ol
2-(2-(4-(Dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol
2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol
2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate (2:1) (salt)
2-(2-(4-Dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
2-(2-(4-dibenzo[b,f]-[1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
2-(2-(4-dibenzo[b,f][1,4] thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethanol; fumaric acid; quetiapine
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol; (E)-but-2-enedioic acid
2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(E)-but-2-enedioic acid
2-[2-(4-benzo[b][1,5]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol
2-[2-(4-dibenzo [b,f ] [1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol fumarate (2:1) (salt)
2-[2-(4-Dibenzo[b, f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol hemifumarate
2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol hemifumarate
2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol
2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol
2-{2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy}ethanol
2C21H25N3O2S.C4H4O4
2S3PL1B6UJ
4769-EP2272537A2
4769-EP2272841A1
4769-EP2275420A1
4769-EP2298731A1
4769-EP2301936A1
4769-EP2308867A2
4769-EP2308870A2
74Q697
974Q697
AB00640033_11
AB00640033_12
AB00640033-09
AB00640033-10
AC-4236
AC1L1JE6
AC1NQXWT
AK116453
AKOS003588973
AKOS015855887
AN-12155
AN-16952
API0004010
AS-12050
BBL029071
BC219347
BDBM50095890
BGL0JSY5SI
BIDD:GT0279
Bio-0083
bis(2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethan-1-ol) fumarate
C07397
C21H25N3O2S
CAS-111974-69-7
CAS-111974-72-2
CCG-213347
CCG-220464
CHEBI:8707
CHEBI:8708
CHEMBL3188993
CHEMBL716
Co-Quetiapine
CS-1171
CTK8F1296
D00458
D08456
D0F9KL
D0H7KF
DB01224
DR002184
DSSTox_CID_24201
DSSTox_CID_3546
DSSTox_GSID_23546
DSSTox_GSID_44201
DSSTox_RID_77073
DSSTox_RID_80114
DTXSID3044201
DTXSID9023546
ETH065
Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-
Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt)
Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-
FT-0658790
fumaric acid; bis(quetiapine)
GTPL50
HMS2089G04
HMS2093K06
HMS2231O11
HMS3372B05
HSDB 7557
HY-14544
I06-1980
I14-0768
ICI 204,636
ICI 204636
ICI-204636
InChI=1/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
J-002679
K-0936
KB-60267
KB-80284
Ketipinor (TN)
KS-1099
L001200
LP067777
LS-172170
LS-66641
M872
MFCD00866699
MFCD03423782
MLS001165710
MLS001195658
MolPort-002-506-329
MolPort-006-069-133
MRF-0000010
NCGC00095911-01
NCGC00095911-03
NCGC00095911-04
NCGC00095911-06
NCGC00255945-01
Norsic
Norsic (TN)
NSC-758918
NSC758918
PD-172760
Pharmakon1600-01505187
Q-201653
quetiapina
quetiapine
Quetiapine (fumarate)
Quetiapine (INN)
Quetiapine [INN:BAN]
Quetiapine for system suitability, European Pharmacopoeia (EP) Reference Standard
Quetiapine fumarate
Quetiapine fumarate (JP17/USAN)
Quetiapine fumarate [USAN]
Quetiapine Fumarate 1.0 mg/ml in Methanol (as free base)
Quetiapine fumarate, European Pharmacopoeia (EP) Reference Standard
Quetiapine Fumarate, Pharmaceutical Secondary Standard; Certified Reference Material
Quetiapine fumarate, United States Pharmacopeia (USP) Reference Standard, monograph mol wt. 883.09 ((C21H25N3O2S)2 ?? C4H4O4)
Quetiapine hemifumarate
Quetiapine hemifumarate salt, >=98% (HPLC)
quetiapinum
RT-015180
RTC-070917
SBI-0206776.P001
SC-19077
SCHEMBL122596
SCHEMBL390694
SCHEMBL7932
Seroquel
Seroquel (Fumarate)
Seroquel (TN)
SMR000550491
SPECTRUM1505187
STL373578
TC-070917
Tox21_111537
Tox21_111537_1
Tox21_302366
UNII-2S3PL1B6UJ
UNII-BGL0JSY5SI
URKOMYMAXPYINW-UHFFFAOYSA-
URKOMYMAXPYINW-UHFFFAOYSA-N
W-5151
ZD 5077
ZD5077
ZINC19632628
ZLA0014
zlchem 12
ZM 204,636
ZM 204636
ZTHJULTYCAQOIJ-WXXKFALUSA-N

US Patents and Regulatory Information for SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SEROQUEL XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 150 mg ➤ Subscribe 2008-11-17
➤ Subscribe Extended-release Tablets 50 mg ➤ Subscribe 2008-10-17
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 2008-06-18
➤ Subscribe Tablets 200 mg and 300 mg ➤ Subscribe 2008-06-12

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
QuintilesIMS
Harvard Business School
McKinsey
Argus Health
Accenture
Dow
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.